Wedbush maintains Outperform rating on ORIC Pharmaceuticals, $14 price target
Wedbush kept an Outperform rating and $14 price target on ORIC Pharmaceuticals, suggesting a 56.3% upside from the last close. The firm cited strong clinical data for ORIC-944 and ORIC-114, with an 88% disease control rate, and the company's strategic focus on cancer therapies.
How this was made

The 30-second read
Why it matters
The analyst's confidence in the pipeline suggests a re‑rating could attract new capital, but the company's small market cap makes the move volatile.
Market read
A fresh Outperform rating with a substantial price target increase provides a short‑term catalyst for ORIC shares.
What to watch
Potential regulatory hurdles and the need for larger trials could delay commercialization.
Background
Wedbush's note highlights early clinical data for ORIC-944 and ORIC-114, noting an 88% disease control rate in heavily pretreated patients.
Ticker impact
Wedbush upgraded ORIC Pharmaceuticals to Outperform with a new $14 price target, implying 56% upside from the recent close.
potential upside as investors price in the new target
The rating change is a fresh analyst opinion with a concrete target, offering a clear catalyst for short‑term demand.
Market effects
Positive sentiment may lift other biotech firms with similar early‑stage pipelines.
Limited to US biotech sector; no broader regional effect.
Minor, confined to investors tracking small‑cap biotech stocks.
Counterpoint
The upgrade may be premature given the early‑stage data and lack of commercial revenue.
Key entities
- AnalystWedbush
Equity research firm providing the rating and price target.
- CompanyORIC Pharmaceuticals
Biopharma developing oncology therapies.
